1-3 of 3
Mark Feinglos, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial

Vivian Fonseca, MD, Roberta McDuffie, MSN, Jorge Calles, MD, Robert M. Cohen, MD, Patricia Feeney, MS, Mark Feinglos, MD, Hertzel C. Gerstein, MD, Faramarz Ismail-Beigi, MD, Timothy M. Morgan, PHD, Rodica Pop-Busui, MD, Matthew C. Riddle, MD, the ACCORD Study Group
Journal: Diabetes Care
Diabetes Care 2013;36(8):2162–2168
https://doi.org/10.2337/dc12-1391
Published: 11 July 2013
View article titled, Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial
Open the PDF for Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial in another window
Includes: Supplementary data
Journal Articles

The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study

Elizabeth R. Seaquist, MD, Michael E. Miller, PHD, Denise E. Bonds, MD, Mark Feinglos, MD, David C. Goff, Jr., MD, Kevin Peterson, MD, Peter Senior, MBBS, for the ACCORD Investigators
Journal: Diabetes Care
Diabetes Care 2012;35(2):409–414
https://doi.org/10.2337/dc11-0996
Published: 16 January 2012
View article titled, The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study
Open the PDF for The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study in another window
Includes: Supplementary data
Journal Articles

Efficacy, Safety, and Dose-Response Characteristics of Glipizide Gastrointestinal Therapeutic System on Glycemic Control and Insulin Secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials

Donald C Simonson, MD, Ione A Kourides, MD, Mark Feinglos, MD, Harry Shamoon, MD, Christine T Fischette, PHD, The Glipizide Gastrointestinal Therapeutic System Study Group
Journal: Diabetes Care
Diabetes Care 1997;20(4):597–606
https://doi.org/10.2337/diacare.20.4.597
Published: 01 April 1997
View article titled, Efficacy, Safety, and Dose-Response Characteristics of Glipizide Gastrointestinal Therapeutic System on Glycemic Control and Insulin Secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials
Open the PDF for Efficacy, Safety, and Dose-Response Characteristics of Glipizide Gastrointestinal Therapeutic System on Glycemic Control and Insulin Secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials in another window